Form 4: Nuvation Bio Inc. Executive Granted Stock Options

Gary Hattersley, Chief Scientific Officer of Nuvation Bio Inc., was granted stock options to purchase 500,000 shares of Class A Common Stock.

Summary

• Gary Hattersley, the Chief Scientific Officer of Nuvation Bio Inc., received stock options on February 29, 2024.
• The options grant Hattersley the right to purchase 500,000 shares of Nuvation Bio Inc.'s Class A Common Stock at an exercise price of $1.87 per share.
• The options vest 25% on the one-year anniversary of the grant date (February 29, 2024), and then monthly over the subsequent 36 months, contingent upon Hattersley's continuous service.
• The options expire on February 27, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it incentivizes management. The sentiment is moderately positive as it suggests confidence in the executive's contribution to the company's future success.

Positives

• The granting of stock options to the Chief Scientific Officer aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company over the long term.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. This grant aligns with standard compensation practices in the sector.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron routinely use stock options to incentivize their leadership teams.
• The vesting schedule and exercise price are typical for such grants, designed to align executive interests with long-term shareholder value.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns executive interests with long-term company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates